Pharma Focus Asia

Clarivate Extends Partnership With Verisim Life to Accelerate and De-risk Research and Drug Development

Wednesday, December 06, 2023

Clarivate Plc (NYSE: CLVT) has introduced the VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence. This integrated platform provides users with a range of predictive insights into compound safety and efficacy, covering factors such as bioavailability, hepatic and renal clearance, clinical toxicity, and first-in-human dose, among others.

This launch represents the continuation of Clarivate's collaboration with VeriSIM Life, an AI-enabled R&D decision de-risker for groundbreaking drug development, as announced earlier in the year.

Robert Poolman, Senior Vice President Life Sciences & Healthcare Products at Clarivate, highlighted the role of AI in reducing research and development time, increasing clinically active compound candidates, and ensuring compliance with regulations. The Translational Index, developed in collaboration with VeriSIM Life, utilizes AI to enhance pre-clinical success rates and provide customers with the insights necessary for innovative treatments and faster delivery to patients.

Jo Varshney, CEO & Founder of VeriSIM Life, emphasized the complexity of translating medicinal candidates into safe and effective therapies. The expanded integration with Clarivate aims to address this complexity, offering solutions that align with researchers' workflows and scientific methods while improving the probability of clinical success.

Acknowledging the pharmaceutical industry's challenges, including unsustainable costs and time associated with translating drug candidates into successful clinical trial outcomes, the collaboration aims to provide accurate, objective data and predictive analytics. This combination of the VeriSIM Life Translational Index and Cortellis Drug Discovery Intelligence facilitates more comprehensive insights, helping researchers accelerate the preclinical translation phase of drug development.

By seamlessly integrating the Translational Index with Cortellis Drug Discovery Intelligence, researchers gain access to AI-enabled insights on toxicology, species-specific drug exposure, and clinical translatability. This empowers them to make informed decisions during critical aspects of drug development, such as route of administration, dosing, toxicity, and human variability.

Clarivate, known for its data integration and deidentified patient solutions, remains committed to supporting customers throughout the entire drug, device, or diagnostic product lifecycle. The company continues to invest in artificial intelligence (AI) and machine learning (ML) to meet the industry's evolving needs, addressing patient unmet needs and engaging stakeholders in new ways.

 

Source: prnasia.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024